Page last updated: 2024-12-04

p-aminohippuric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID2148
CHEMBL ID463
CHEBI ID104011
SCHEMBL ID196513
MeSH IDM0015718

Synonyms (144)

Synonym
smr001233372
MLS002154055
pah (amino acid)
4-aminohippuric acid
nefrotest
n-(4-aminobenzoyl)glycine
aminohippuric acid
hippuric acid, p-amino-
glycine, n-(4-aminobenzoyl)-
nsc-7550
n-(p-aminobenzoyl)glycine
PAH ,
nsc7550
p-aminohippuric acid
61-78-9
DIVK1C_000694
KBIO1_000694
n-[(4-aminophenyl)carbonyl]glycine
SPECTRUM_001310
PRESTWICK3_000895
nsc13064
nsc-13064
cas-61-78-9
NCGC00016279-01
BSPBIO_000710
OPREA1_490712
BPBIO1_000782
2-[(4-aminobenzoyl)amino]acetic acid
IDI1_000694
inchi=1/c9h10n2o3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4h,5,10h2,(h,11,14)(h,12,13
AB00052309
p-aminohippuric acid, >=99%
para-aminohippuric acid
p-aminohippurate
n-(para-aminobenzoyl)glycine
paraaminohippuric acid
DB00345
paha
para-aminohippurate
n-(p-aminobenzoyl)aminoacetic acid
aminohippurate
PRESTWICK2_000895
NCGC00094993-01
NCGC00094993-02
nsc 13064
ai3-52275
hsdb 2139
einecs 200-518-9
KBIO3_002044
KBIO2_004358
KBIO2_001790
KBIOSS_001790
KBIOGR_001390
KBIO2_006926
SPECTRUM3_000952
PRESTWICK0_000895
SPECTRUM4_001065
SPBIO_001589
SPECTRUM2_001515
PRESTWICK1_000895
NINDS_000694
SPBIO_002919
SPECTRUM1503069
SPECTRUM5_001100
D06890
aminohippuric acid (usp)
HMS2092H18
A0313
aminohippuric acid, p-
CHEMBL463
HMS502C16
HMS1570D12
HMS1922C07
STK801822
CHEBI:104011 ,
AKOS000120722
A833420
HMS2097D12
nsc-758232
nsc758232
pharmakon1600-01503069
tox21_110345
dtxcid902590
dtxsid7022590 ,
2-(4-aminobenzamido)acetic acid
n-(p-aminobenzoyl)aminoacetate
4-aminohippurate
HMS2233A21
CCG-39181
NCGC00016279-02
NCGC00016279-03
aminohippuric acid [usp]
y79xt83bj9 ,
unii-y79xt83bj9
FT-0617576
FT-0622289
aminohippuric acid [hsdb]
aminohippuric acid [usp-rs]
aminohippuric acid [usp monograph]
p-aminohippuric acid [mi]
aminohippuric acid [who-dd]
aminohippuric acid [mart.]
S2883
HMS3373E19
2-[(4-aminophenyl)formamido]acetic acid
gtpl4810
BBL027666
SCHEMBL196513
tox21_110345_1
NCGC00016279-05
CS-4816
W-203306
(p-aminobenzoyl)glycine
HSMNQINEKMPTIC-UHFFFAOYSA-N
[(4-aminobenzoyl)amino]acetic acid #
4-aminohippuric acid biotech
HY-B1306
AC-29237
AB00052309_08
4-amino hippuric acid
mfcd00007890
4-aminohippuric-d4 acid
sr-05000002048
(4-aminobenzoyl)glycine
p-aminohippuric acid, >=98.0% (t)
aminohippuric acid, united states pharmacopeia (usp) reference standard
HMS3651L04
SR-05000002048-1
SR-05000002048-3
SBI-0051760.P002
HMS3714D12
SW197249-3
BCP04299
n-(4-aminobenzoyl-d4)glycine
Q291271
A16384
4-aminohippuricacid
7E-944
4-aminohippuric-acid
D88242
A936052
EN300-20920
SY048511
Z104484866

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Probenecid, when administered sc to F344 rats 1 hour prior to an iv LD50 dose of cis-dichlorodiammineplatinum(II) (CDPP), reduced significantly the peak BUN and serum creatinine levels which occurred 4 days following CDDP."( Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.
Gale, GR; Ross, DA, 1979
)
0.26
"The acute toxic effects of thiabendazole [2-(4'-thiazolyl)benzimidazole; TBZ] on the kidneys of ICR mice were investigated."( Acute renal toxicity of thiabendazole (TBZ) in ICR mice.
Fujitani, T; Tada, Y; Yoneyama, M, 1992
)
0.28
" However, the inability of CPZ to markedly attenuate NDHS nephrotoxicity could indicate that CPZ protected against NDPS nephrotoxicity by inhibiting biotransformation of the parent compound to its toxic chemical species."( Effect of calcium antagonism by nifedipine and chlorpromazine on acute N-(3,5-dichlorophenyl)succinimide-induced nephrotoxicity in Fischer 344 rats.
Brown, PI; Nicoll, DW; Rankin, GO; Sutherland, CH; Teets, VJ; Valentovic, MA, 1991
)
0.28
" CBDCA-induced MDA production was lower, compared to CDDP, which showed marked toxic effects on TEA and PAH accumulation, gluconeogenesis and glucose-6-phosphatase activity."( Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.
Baumann, K; Hannemann, J, 1990
)
0.28
" The results indicated that 4-methyl-2,3-dihydrofuran and 4-ethyl-2,3-dihydrofuran were toxic to the lung whereas 4-pentyl-2,3-dihydrofuran did not produce lung toxicity."( Toxicity of alkyldihydrofurans to metabolically active organs in the mouse.
Bresnahan, J; Brinkman, R; Gammal, L; Penka, V; Traiger, G; Wiley, R; Zenk, P, 1990
)
0.28
" When we administered the combination of captopril (100 mg X kg-1 X day-1) and gentamicin in potassium-depleted rats, we observed a surprising and significant adverse effect of this combination on the clearances of inulin (CIn) and PAH (CPAH) and renal blood flow (RBF)."( Captopril enhances aminoglycoside nephrotoxicity in potassium-depleted rats.
Baker, JD; Boatman, JE; Klotman, PE; Volpp, BD; Yarger, WE, 1985
)
0.27
" In contrast apical treatment with PCBD-NAC was only toxic at high concentrations (greater than 850 microM), and this effect could hardly be inhibited by AOAA."( Differential toxicity as a result of apical and basolateral treatment of LLC-PK1 monolayers with S-(1,2,3,4,4-pentachlorobutadienyl)glutathione and N-acetyl-S-(1,2,3,4,4-pentachlorobutadienyl)-L-cysteine.
Mertens, JJ; Spenkelink, B; Temmink, JH; van Bladeren, PJ; van Doorn, WJ; Weijnen, JG, 1988
)
0.27
" The purpose of this study was to examine if an arene oxide intermediate is a toxic metabolite contributing to NDPS-induced nephropathy in rats."( Acute N-(3,4,5-trichlorophenyl)succinimide-induced nephrotoxicity in Sprague-Dawley and Fischer-344 rats.
Brown, PI; Lahoda, EP; Rankin, GO; Yang, DJ, 1986
)
0.27
" Pretreatment with phenobarbital enhanced the toxic response of renal cortical slices to CHCl3 in vitro as indicated by decreased p-aminohippurate and tetraethylammonium accumulation."( Mechanism of chloroform nephrotoxicity. IV. Phenobarbital potentiation of in vitro chloroform metabolism and toxicity in rabbit kidneys.
Bailie, MB; Hook, JB; Newton, JF; Smith, JH, 1984
)
0.27
" The results with PiBx suggest that either the parent compound possesses some direct cytotoxicity or that a toxic metabolite was generated through a biotransformation pathway not inhibited by PiBx."( 3,5-Dichloroaniline toxicity in Fischer 344 rats pretreated with inhibitors and inducers of cytochrome P450.
Brown, PI; Lo, HH; Rankin, GO; Valentovic, MA, 1995
)
0.29
"5-2 mmol l-1) ameliorated all these toxic effects of cisplatin in a concentration related manner."( Amelioration of cisplatin toxicity in rat renal cortical slices by dithiothreitol in vitro.
Lindup, WE; Ma, XL; Xia, YX; Zhang, JG; Zhang, M; Zhong, LF, 1994
)
0.29
"Aminoglycoside nephrotoxicity remains a common clinical problem and is the major cause of acute toxic renal failure in hospitalized patients."( Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits.
Amirault, P; Blanchet, F; Carbon, C; Heudes, D; Lortholary, O; Nochy, D; Seta, N, 1993
)
0.29
" The purpose of this study was to define the toxic effect and excretion of cisplatin in the chicken, a species widely applied to the study of tubular transport mechanisms but little used for toxicology studies."( Toxicity and excretion of cisplatin in the avian kidney.
Cacini, W; Fink, IM, 1995
)
0.29
" The mechanism of protection conferred to rats by an ADT pretreatment against HCBD-induced nephrotoxicity appears to take place in the kidney at a step beyond the generation of ultimate toxic metabolites derived from PCBC."( Assessment of the role of glutathione conjugation in the protection afforded by anethol dithiolthione against hexachloro-1,3-butadiene-induced nephrotoxicity.
Bouthillier, L; Brodeur, J; Charbonneau, M, 1996
)
0.29
" Pretreatment of slices with tiopronin for 60 min also significantly protected the renal slices from cisplatin-induced toxic effects."( Tiopronin protects against the nephrotoxicity of cisplatin in rat renal cortical slices in vitro.
Lindup, WE; Zhang, JG, 1996
)
0.29
" Addition of 200 microM DMPS to the bath provided complete protection from the toxic effects of 20 microM inorganic mercury in the lumen."( Mechanisms of action of 2,3-dimercaptopropane-1-sulfonate and the transport, disposition, and toxicity of inorganic mercury in isolated perfused segments of rabbit proximal tubules.
Barfuss, DW; Cannon, VT; Parks, LD; Zalups, RK, 1998
)
0.3
" The present study was therefore carried out to determine the mechanism and the exact sequence of events that lead to molecular toxic injury."( Atractyloside nephrotoxicity: in vitro studies with suspensions of rat renal fragments and precision-cut cortical slices.
Bach, PH; Obatomi, DK, 2000
)
0.31
"This report demonstrates decreased PAH clearance as a late renal side effect of chemotherapy and suggests disturbed function of the organic anion transport system."( Impaired tubular excretory function as a late renal side effect of chemotherapy in children.
Hotta, H; Ikarashi, Y; Imai, C; Kakihara, T; Tanaka, A; Uchiyama, M, 2003
)
0.32
"Renal injury is a common side effect of the chemotherapeutic agent ifosfamide."( Ifosfamide toxicity in cultured proximal renal tubule cells.
Springate, J; Taub, M, 2007
)
0.34

Pharmacokinetics

ExcerptReferenceRelevance
" Results showed that at systemic endothelin-1 plasma concentrations, comparable to those which occur in a variety of pathologic conditions such as hypertension or cardiogenic shock, besides pulmonary clearance, renal and limb uptake of the peptide may also contribute to the short half-life (t1/2) of endothelin-1 in humans."( Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide.
Gasic, S; Nowotny, P; Vierhapper, H; Wagner, OF; Waldhäusl, W, 1992
)
0.28
" For interpretation of clinical findings, extensive pharmacokinetic studies were performed on patients."( Pharmacokinetics of technetium-99m-MAG3 in humans.
Brandau, W; Bubeck, B; Georgi, P; Kälble, T; Parekh, N; Weber, E, 1990
)
0.28
" The kinetics of the drug (including plasma drug levels, plasma half-life and plasma clearance) and its effects on renal function were observed for 24 hours."( Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.
Campese, VM; Massry, SG; Solimon, M, 1986
)
0.27
" The use of urethane as an anesthetic in pharmacokinetic studies still persists, particularly in experiments of long duration."( Possible hemodynamic basis to urethane anesthesia-induced reductions in renal clearance.
Gumbleton, M; Nicholls, PJ; Taylor, G,
)
0.13
" In step 1, the computer program was used to estimate the average pharmacokinetic parameters without taking into account the demographic and/or biological factors."( Bayesian estimation of p-aminohippurate clearance by a limited sampling strategy.
Augey, V; Bressolle, F; Fabre, D; Galtier, M; Gomen, R; Kinowski, JM; Richard, JL; Rodier, M, 1995
)
0.29
"In traditional pharmacokinetic models, blood flow or liquid transit is often expressed as first-order kinetics."( Preliminary Flow Modeling by Hybrid Automata Alternating Continuous Reaction and Discrete Transit for Pharmacokinetics.
Koyama, S, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" In vivo and in vitro studies were conducted to evaluate the renal drug-drug interaction potential of oseltamivir."( The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Barrett, J; Cihlar, T; Hill, G; Ho, ES; Liu, B; Oo, C; Prior, K; Ward, P; Wiltshire, H, 2002
)
0.31
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" administration of ampicillin sodium (20 mg/kg), ampicillin concentrations were systematically higher after a 3-day period of water deprivation than during the control period but the muscular absorption rate was not modified."( Effect of water deprivation on absorption (oral, intramuscular) and disposition of ampicillin in sheep.
Oukessou, M; Toutain, PL, 1992
)
0.28
" Bioavailability of probenecid was 117 and 102% for 2 mares after a single intragastric dose, compared with a single IV dose."( Probenecid infusion in mares: effect on para-aminohippuric acid clearance.
Brown, MP; Gronwall, R, 1988
)
0.27
" The addition of SITS, DIDS, or furosemide to the luminal perfusion solution resulted in a decreased rate of absorption of water and 2-14C-urate."( Effect of anion exchange inhibitors and para-aminohippurate on the transport of urate in the rat proximal tubule.
Bennett, S; Kahn, AM; Sansom, SC; Weinman, EJ, 1983
)
0.27
" Serum IGFBP-3 levels fell while IGFBP-1 and -2 levels rose during treatment, changes that likely affect the bioavailability of IGF-I."( Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure.
Fervenza, FC; Hintz, RL; Hoffman, AR; Ike, JO; Liu, F; Rabkin, R; Yeh, I, 1997
)
0.3
" VACV demonstrates an oral bioavailability that is three to five time greater than acyclovir, concentration dependent, and saturable in humans."( Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats.
Balimane, PV; Sinko, PJ, 1998
)
0.3
" Limited bioavailability of glutamine may affect arginine synthesis, which may have consequences for nitric oxide (NO) synthesis."( Renal amino acid metabolism during endotoxemia in the rat.
Cobben, DC; Dejong, CH; Deutz, NE; Hallemeesch, MM; Soeters, PB, 2000
)
0.31
" bioavailability may represent a common factor responsible for the vascular and glomerular dysfunction."( Oxidative stress and renal dysfunction in salt-sensitive hypertension.
Loscalzo, J; Rudd, MA; Trolliet, MR, 2001
)
0.31
"It is known that secretory transport limits the oral bioavailability of certain drugs."( Characterization of secretory intestinal transport of phenolsulfonphthalein.
Chiba, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Miyazaki, K; Shimamoto, S; Sugawara, M, 2005
)
0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" When the data were normalized for anesthetic potency, all agents exhibited a parallel dose-response curve."( In vitro inhibition of rho-aminohippurate transport by halogenated anesthetics.
Bastron, RD; Kaloyanides, GJ; Perkins, FM, 1977
)
0.26
" The present observations and those of other authors working in this area are discussed and an approach to drug dosage of renally excreted drugs in kwashiorkor has been proposed."( Penicillin pharmacokinetics in kwashiorkor.
Buchanan, N; Eyberg, C; Koornhof, HJ; Robinson, R, 1979
)
0.26
" Single administration of potassium dichromate or glycerol is followed by a marked decrease of renal PAH excretion in dependence on the time after the administration as well as on the dosage used."( Stimulation of kidney function in rats of different ages injured by nephrotoxic agents.
Bräunlich, H; Fleck, C; Stopp, M; Weise, C, 1979
)
0.26
" In a dosage of 100 and 300 mg/day benzbromaron proved to be a much more potent uricosuricum."( [The uricosuric effect of benzbromaron and probenecid under fasting conditions (author's transl)].
Kleinschmidt, A; Schräpler, P; Schulz, E, 1978
)
0.26
" The concentration of TBZ in blood at 1 or 5 hr after dosing was lower in mice pretreated with microsomal monooxygenase system inducers and was higher in those pretreated with the inhibitors, than in those given TBZ alone."( Acute renal toxicity of thiabendazole (TBZ) in ICR mice.
Fujitani, T; Tada, Y; Yoneyama, M, 1992
)
0.28
" Cld did not cause any significant changes in tissue malondialdehyde (MDA) content in vivo at any of the time points examined, but it did cause a depletion of GSH to approximately 40% of control by 1 hr after dosing that recovered toward control by 6 hr."( Cephaloridine-induced renal pathological and biochemical changes in female rabbits and isolated proximal tubules in suspension.
Engelhardt, J; Heim, RA; Ponsler, GD; Rush, GF, 1992
)
0.28
" The therapeutic relevance of the results are discussed for a better definition of dosage regimens for sheep reared in arid environments."( Effect of water deprivation on absorption (oral, intramuscular) and disposition of ampicillin in sheep.
Oukessou, M; Toutain, PL, 1992
)
0.28
" The dose-response curves for AZT and probenecid, an organic anion inhibitor, revealed IC50 values of 225 and 15 microM, respectively."( Interaction of 3'-azido-3'-deoxythymidine with organic ion transport in rat renal basolateral membrane vesicles.
Griffiths, DA; Hall, SD; Sokol, PP, 1991
)
0.28
" A dose-response curve was constructed for DQ-2556 inhibition of NMN transport in rat BBMV."( Effect of DQ-2556, a new cephalosporin, on organic ion transport in renal plasma membrane vesicles from the dog, rabbit and rat.
Sokol, PP, 1990
)
0.28
" We conclude that at effective beta-blocking dosage SE2395 does not induce any detrimental effect on renal function in conscious dogs."( Cardiovascular and renal effects of the beta-blocker SE2395 in conscious normotensive dogs.
Burke, TJ; Erickson, AL; Prost, JF; Rochat, C; Walker, BR,
)
0.13
" Enalapril was then administered for 72 hours and 6 weeks, and the assessment of the Ang II dose-response relations was repeated."( Prolonged converting enzyme inhibition in non-modulating hypertension.
Dluhy, RG; Hollenberg, NK; Smith, K; Taylor, T; Williams, GH, 1989
)
0.28
" with TCE in a dosage of 125-1000 mg/kg in sesame oil."( Lipid peroxidation: a possible mechanism of trichloroethylene-induced nephrotoxicity.
Beuter, W; Cojocel, C; Mayer, D; Müller, W, 1989
)
0.28
" Renal impairment did not change the percentages of the bevantolol dosage excreted unchanged or as conjugated drug in the urine, and no toxic or active drug metabolites accumulated in the blood."( Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.
Campese, VM; Massry, SG; Solimon, M, 1986
)
0.27
" A dose-response curve for MPTP and its oxidized metabolite, MPP+, revealed IC50 values of 160 and 16 microM, respectively."( The neurotoxins 1-methyl-4-phenylpyridinium and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine are substrates for the organic cation transporter in renal brush border membrane vesicles.
Holohan, PD; Ross, CR; Sokol, PP, 1987
)
0.27
" Recommendations have been done on selection and dosage of test substances, timing of examination and evaluation of results."( [Standardization of methods and assessment of conventional and radionuclide clearance investigations: recommendations of the Renal Diagnostics Study Group of the Society of Nephrology, GDR].
Devaux, S; Esther, G; Mende, T; Schumann, L; Sydow, K; Wüstenberg, PW, 1988
)
0.27
" At a dosage of 200 mg/kg, probenecid accumulated in the serum from the 1st to the 5th dose."( Probenecid infusion in mares: effect on para-aminohippuric acid clearance.
Brown, MP; Gronwall, R, 1988
)
0.27
" Based on the prolonged blockade of plasma ACE activity, some correction in dose or dosing interval is anticipated in patients with moderately compromised renal function (CLCR less than 50 ml/min)."( Effect of renal impairment on disposition of pentopril and its active metabolite.
Audet, PR; Feldman, GM; Hurley, ME; Kochak, GM; Radensky, P; Rakhit, A; Szerlip, HM, 1988
)
0.27
" These results indicate that a proper dosage adjustment may have to be made in the dehydration condition, especially for drugs whose disposition is dependent on GFR."( Effect of acute water deprivation on renal function in rats.
Jung, D; Niazi, S; Prasad, P,
)
0.13
" Urine samples were obtained from healthy Chinese volunteers after oral dosing of 200 mg PABA which was used as a model substance for metabolic investigation of N-acetylation and other conjugation reactions."( High performance liquid chromatographic characterisation and quantitation of p-aminobenzoic acid N-acetylation in Chinese subjects.
Chan, K,
)
0.13
" One-step extraction of UTXB2 with an octadecylsilyl-silica column was sufficient as pretreatment for TXB2 radioimmunoassay because recovery of UTXB2 was good, the eluate was parallel with the dose-response curve, and the value coincided with that obtained by the conventional method."( Increased thromboxane B2 excretion in diabetes mellitus.
Inaba, M; Ishii, J; Katayama, S; Kawazu, S; Maruno, Y; Omoto, A, 1987
)
0.27
" Tolerance to the acute effects of morphine on phenol red disposition is probably due to lessened response of blood flow or tubular function in chronically dosed mice."( Tolerance to morphine effects on renal disposition of xenobiotics in mice.
Garty, M; Hurwitz, A, 1986
)
0.27
" Inulin and para-aminohippuric (PAH) clearances, natriuresis, and fractional excretion of sodium increased significantly after intravenous dosing with dopamine (2 micrograms/min/kg) in both groups."( Enhanced dopamine renal responsiveness in patients with hypertension.
Andrejak, M; Hary, L, 1986
)
0.27
"The dopamine alpha- and beta-adrenoceptor dose-response curves are investigated in four patients who are exempt from cardiovascular disease."( The use of low doses of dopamine in intensive care medicine.
D'Orio, V; el Allaf, D; Juchmès, J; Marcelle, R, 1984
)
0.27
" Dose-response data for ouabain inhibition of PAH transport and tubule Na,K-adenosine triphosphatase (ATPase) activity were identical."( Heavy metal inhibition of p-aminohippurate transport in flounder renal tissue: sites of HgCl2 action.
Miller, DS, 1981
)
0.26
" The shapes of the dose-response curves for inhibition of the organic cation and organic anion transport are different, and the inhibition is competitive in each case."( Mechanisms for the renal secretion of cisplatin.
Herbert, BH; Nelson, JA; Santos, G, 1984
)
0.27
" Compared with probenecid, thimerosal and mercaptide V yielded dose-response curves of steeper slope and higher maximal effect."( Effects of analogs of salicylate on p-aminohippurate uptake into basal-lateral membranous vesicles.
Bildstein, C; Liu, D; Mamelok, RD; Tse, SS, 1984
)
0.27
" In rats of all age-groups, the glomerularly filtered PAH proportion increases with increasing dosage (kinetics in decreasing blood level)."( [Dose- and age-dependence of the renal tubular transport of p-aminohippuric acid (PAH) in rats after injection of single doses].
Bajanowski, T; Bräunlich, H; Fleck, C; Miosge, W, 1983
)
0.51
"offstudied hemodynamic and renal effects of increasing the dosage of dopamine (DP) by 5 micrograms/kg X min, in 7 patients with peritonitis and clinical findings of septic shock, all of whom were already receiving variable dosages of DP."( Dose-related hemodynamic and renal effects of dopamine in septic shock.
de la Cal, MA; Esteban, A; Miravalles, E; Pascual, T; Ruiz-Santana, S, 1984
)
0.27
" The dose-response curves for three different inhibitors were identical for the OH- and Cl- gradient-stimulated modes of urate uptake."( Urate transport via anion exchange in dog renal microvillus membrane vesicles.
Aronson, PS; Kahn, AM, 1983
)
0.27
" In the dosage range under study, the probenecid homologues show linear dose-response relationships."( [Inhibition of the renal excretion of PAH by probenecid homologs].
Appenroth, D; Bräunlich, H, 1983
)
0.27
"Effects of intravenous and long-term oral dosing with pindolol on renal function were examined in eight hypertensive patients with reduced renal function."( Effects of pindolol on renal function II. Effects on intravenous and prolonged oral dosing.
Boner, G; Rosenfeld, JB; Wainer, E, 1982
)
0.26
" The purpose of our study was to assess the influence of oral dosing vehicle on the acute hepatotoxicity of CCl4 and nephrotoxicity of CHCl3."( Effect of dosing vehicle on the hepatotoxicity of CCl4 and nephrotoxicity of CHCl3 in rats.
Plaa, GL; Raymond, P, 1997
)
0.3
"Elimination of drug molecules via tubular secretion is an important pharmacokinetic parameter especially for oral dosage forms where an extremely short half-life would prevent their application."( Inhibition of the conjugation of PABA with glycine in vitro by sulfamoyl benzoic acids, sulfonamides, and penicillins and its relation to tubular secretion.
Ehlert, C; Seydel, JK; Strunz, H; Visser, K; Wiese, M, 1998
)
0.3
" Only with 7 days highest dosage treatment PAH excretion was reduced significantly by CsA and CsA + D treatment."( Is there a beneficial effect of the calcium channel blocker diltiazem on cyclosporine A nephrotoxicity in rats?
Balogh, A; Fleck, C; Kostka, E; Kühl, A; Kuhn, UD; Lupp, A; Stein, G, 1998
)
0.3
"Postoperative renal dysfunction in rats is induced by ketorolac dosed concurrently with gentamicin."( Renal dysfunction associated with the perioperative use of diclofenac.
Cousins, MJ; Eckstein, RP; Jordan, V; Kim, H; Lin, Y; Mather, LE; Power, I; Xu, M, 1999
)
0.3
" These dose-response data may serve as useful contributions when assessing environmental risk with regard to marine oil pollution."( PAH metabolites in bile, cytochrome P4501A and DNA adducts as environmental risk parameters for chronic oil exposure: a laboratory experiment with Atlantic cod.
Aas, E; Andersen, OK; Balk, L; Baussant, T; Liewenborg, B, 2000
)
0.31
"Clearances of inulin and PAH decreased progressively after CsA dosage while renal vascular resistance increased."( Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide?
Bernemann, A; Bickeböller, R; Gossmann, J; Raab, HP; Radounikli, A; Schellinski, O; Scheuermann, EH, 2001
)
0.31
" Dosage alterations ofrenally eliminated drugs may be required for drugs with a narrow therapeutic index."( Evaluation of renal function in transplant patients on tacrolimus therapy.
Agarwala, S; Burckart, G; Chakrabarti, P; Culligan, E; Jain, A; McCauley, J; Shapiro, R; Venkataramanan, R, 2002
)
0.31
" To examine the dose-response effects of CM on gluconeogenesis and p-aminohipuric acid (PAH) accumulation in the rat renal slices, slices were incubated with 30, 60, and 90 mg I/ml of CM."( Inhibition of gluconeogenesis and p-aminohipuric acid accumulation in rat renal cortical slices by ionic and nonionic contrast media.
Kanou, T; Naito, S; Nakamura, M; Soejima, K; Tokuda, N; Uozumi, J, 2003
)
0.32
" No adjustment of the recommended PO dosage of ramipril is needed in dogs with moderate renal impairment."( Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Jeunesse, E; Laroute, V; Lefebvre, HP; Toutain, PL,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Daphnia magna metaboliteA Daphnia metabolite produced by the species Daphnia magna.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
N-acylglycineAn N-acyl-amino acid in which amino acid specified is glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.62340.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency29.90330.180013.557439.8107AID1460; AID1468
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.01190.00137.762544.6684AID914; AID915
gemininHomo sapiens (human)Potency19.95260.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)67.90000.27004.53069.9000AID679324; AID681331
Solute carrier family 22 member 6Homo sapiens (human)Ki6.02000.03003.20437.8200AID598877; AID678821
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)1,300.00000.18003.68578.8000AID681159
Solute carrier family 22 member 20Mus musculus (house mouse)Ki446.34201.10006.67899.1201AID360149
Solute carrier family 22 member 8Homo sapiens (human)Ki19.60000.04004.22979.0000AID678814
Solute carrier family 22 member 6Mus musculus (house mouse)Ki9.36630.40745.02179.4000AID360150
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)4,500.00001.00004.446710.0000AID681158
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)Ki683.00003.09005.54009.1000AID679175; AID679176; AID679290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Km48.72000.57001.33502.1000AID679485; AID680338; AID681362; AID681741; AID681742
Multidrug resistance-associated protein 1 Homo sapiens (human)Km372.00000.73002.65505.0000AID681077
Solute carrier family 22 member 6Homo sapiens (human)Km10.77780.42004.61839.3000AID1219946; AID678820; AID679321; AID679323; AID679372; AID679375; AID679380; AID679383; AID682074
Solute carrier family 22 member 8Homo sapiens (human)Km87.20000.34501.32173.1000AID681141
Canalicular multispecific organic anion transporter 1Homo sapiens (human)Km880.00007.20008.30009.4000AID679663
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)Km64.70000.73901.53952.3400AID678967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (55)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (152)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID680482TP_TRANSPORTER: inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 uM, PAH: 2500 uM) in MDR1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Aug, Volume: 282, Issue:2
Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
AID678967TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of biological chemistry, May-07, Volume: 274, Issue:19
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
AID1552652Substrate activity at human OAT1 expressed in HEK293 cells harboring pEGFP assessed as compound uptake measured after 20 mins by UPLC-MS/MS method2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Synthesis, pharmacological evaluation, and mechanistic study of adefovir mixed phosphonate derivatives bearing cholic acid and l-amino acid moieties for the treatment of HBV.
AID388274Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase relative to hippuric acid2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID679485TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID680338TP_TRANSPORTER: uptake in OAT1-expressing S3 cells1999Kidney international, Dec, Volume: 56, Issue:6
Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity.
AID1219951Drug transport in human OAT1 expressed in HEK Flp-In cells at 0.12 uM for 10 mins relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID360152Activity of mouse Oat6 expressed in Xenopus oocytes assessed as drug uptake2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681159TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1744121Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID681416TP_TRANSPORTER: inhibition of Homovanillic acid uptake (HVA: 0.2 uM, PAH: 1000 uM) in Xenopus laevis oocytes2003Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Apr, Volume: 23, Issue:4
Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID681799TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, PAH: 200 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
AID680168TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, PAH: 200 uM) in OAT4-expressing S2 cells2002Biochimica et biophysica acta, Jun-12, Volume: 1590, Issue:1-3
Role of human organic anion transporter 4 in the transport of ochratoxin A.
AID681575TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998FEBS letters, Jun-12, Volume: 429, Issue:2
Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.
AID681386TP_TRANSPORTER: uptake in mOat3-expressing oocytes2004Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 32, Issue:5
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
AID598877Inhibition of human Oat1 expressed in Drosophila S2 cells2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID679323TP_TRANSPORTER: uptake in OAT1-expressing CHO cells2000Journal of the American Society of Nephrology : JASN, Mar, Volume: 11, Issue:3
Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681742TP_TRANSPORTER: uptake in Oat1-expressing LLC-PK1 cells2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.
AID679324TP_TRANSPORTER: inhibition of Urate uptake (Urate: 300 uM) in OAT1-expressing S2 cells2003Kidney international, Jan, Volume: 63, Issue:1
Urate transport via human PAH transporter hOAT1 and its gene structure.
AID681077TP_TRANSPORTER: uptake in membrane vesicle from MRP1-expressing HeLa cells2000Kidney international, Apr, Volume: 57, Issue:4
ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2.
AID679380TP_TRANSPORTER: uptake in OAT1-expressing OK cells2002British journal of pharmacology, Jan, Volume: 135, Issue:2
Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake.
AID679962TP_TRANSPORTER: uptake in Oatp1-expressing HeLa cells1996The American journal of physiology, Feb, Volume: 270, Issue:2 Pt 2
Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates.
AID678971TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of biological chemistry, Feb-11, Volume: 275, Issue:6
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681331TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID678821TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT1-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID680534TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, PAH: 500 uM) in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID679372TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The American journal of physiology, 01, Volume: 276, Issue:1
Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney.
AID388272Activity of rat recombinant peptidylglycine alpha-amidating monooxygenase assessed as stimulation of oxygen consumption2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID679290TP_TRANSPORTER: inhibition of E217betaG uptake in Oat3-expressing LLC-PK1 cells2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.
AID682300TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, PAH: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID682169TP_TRANSPORTER: inhibition of benzylpenicillin uptake by P-aminohippuric acid at a concentration of 1000uM in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID681168TP_TRANSPORTER: uptake in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID681371TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Molecular pharmacology, Jul, Volume: 62, Issue:1
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681015TP_TRANSPORTER: uptake in OAT-expressing COS-7 cells1999The Journal of biological chemistry, Jan-15, Volume: 274, Issue:3
Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.
AID1219945Drug transport in human OAT1 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID1146770Competitive inhibition of Escherichia coli B H2-pteroate synthetase assessed as decrease in H2-pteroate formation using [7-14C]-PABA as substrate treated with enzyme for 10 mins prior to substrate challenge for 40 mins by radioassay method1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
P-Aminobenzoic acid derivatives as inhibitors of the cell-free H2-pteroate synthesizing system of Escherichia coli.
AID680398TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, PAH: 5000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID678813TP_TRANSPORTER: trans-stimulation in Xenopus laevis oocytes2003Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 13, Issue:5
Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux.
AID678795TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID679176TP_TRANSPORTER: inhibition of PCG uptake in Oat3-expressing LLC-PK1 cells2002Molecular pharmacology, May, Volume: 61, Issue:5
Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.
AID679175TP_TRANSPORTER: inhibition of Pravastatin uptake in Oat3-expressing LLC-PK1 cells2002The Journal of pharmacology and experimental therapeutics, Mar, Volume: 300, Issue:3
Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions.
AID681158TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID588964Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID679375TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Interaction of 2,3-dimercapto-1-propane sulfonate with the human organic anion transporter hOAT1.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678820TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Molecular pharmacology, Sep, Volume: 56, Issue:3
The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.
AID679548TP_TRANSPORTER: conventional two electrode voltage-clamp technique in OAT1-MDCK cells2003American journal of physiology. Renal physiology, Oct, Volume: 285, Issue:4
Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells.
AID679663TP_TRANSPORTER: uptake in membrane vesicles from MRP2-expressing HEK cells2000Kidney international, Apr, Volume: 57, Issue:4
ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID679717TP_TRANSPORTER: uptake of P-Aminohippuric acid at a concentration of 9uM in MCT1-expressing MDA-MB231 cells1999The Journal of pharmacy and pharmacology, Oct, Volume: 51, Issue:10
Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1.
AID360153Activity of mouse Oat1 expressed in Xenopus oocytes assessed as drug uptake2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID682074TP_TRANSPORTER: uptake in OAT1-MDCK cells2003American journal of physiology. Renal physiology, Oct, Volume: 285, Issue:4
Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells.
AID681221TP_TRANSPORTER: inhibition of PGE2 uptake (PGE2: 0.015 uM) by P-aminohippuric acid at 0.15uM in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID679692TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999FEBS letters, Oct-01, Volume: 459, Issue:1
Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID681741TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997The Journal of biological chemistry, Nov-28, Volume: 272, Issue:48
Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney.
AID1219947Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT1 expressed in HEK Flp-In cells measured per mg of protein2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID679204TP_TRANSPORTER: inhibition of TEA uptake (TEA: 500 uM, PAH: 5000 uM) in OCT1A expressing Xenopus laevis oocytes1997The Journal of biological chemistry, Jun-27, Volume: 272, Issue:26
Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679321TP_TRANSPORTER: uptake in OAT1-expressing HeLa cells1999The American journal of physiology, 02, Volume: 276, Issue:2
Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C.
AID35123Compound was evaluated at 100 uM for the ability to inhibit partially purified aldose reductase obtained from rat lens1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and in vitro aldose reductase inhibitory activity of compounds containing an N-acylglycine moiety.
AID679707TP_TRANSPORTER: inhibition of MTX uptake (MTX: 0.01 uM, PAH: 100 uM) in OAT-K1-expressing MDCK cells1999FEBS letters, Oct-01, Volume: 459, Issue:1
Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane.
AID679383TP_TRANSPORTER: uptake in OAT1-COS7 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Interaction of cysteine conjugates with human and rabbit organic anion transporter 1.
AID678986TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID681141TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID388273Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID678961TP_TRANSPORTER: uptake in OAT2-expressing EcR293 cells2001Biochemical and biophysical research communications, May-04, Volume: 283, Issue:2
Isolation of a family of organic anion transporters from human liver and kidney.
AID1744122Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679477TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002The Journal of biological chemistry, Jul-26, Volume: 277, Issue:30
Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice.
AID680344TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Pflugers Archiv : European journal of physiology, Nov, Volume: 443, Issue:2
Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3.
AID680760TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.004 uM, PAH: 500 uM) in Xenopus laevis oocytes2003The Journal of pharmacy and pharmacology, Jul, Volume: 55, Issue:7
Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin.
AID681362TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997The Journal of biological chemistry, Jul-25, Volume: 272, Issue:30
Expression cloning and characterization of a novel multispecific organic anion transporter.
AID681149TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Pflugers Archiv : European journal of physiology, Nov, Volume: 443, Issue:2
Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3.
AID34960Inhibition of aldose reductase from rat lens;ND is not determined.1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and in vitro aldose reductase inhibitory activity of compounds containing an N-acylglycine moiety.
AID1552680Selectivity ratio, ratio of substrate activity at human OAT1 expressed in HEK293 cells harboring pEGFP assessed as compound uptake to substrate activity in human HEK293 cells harboring pEGFP-N1 empty vector assessed as compound uptake2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Synthesis, pharmacological evaluation, and mechanistic study of adefovir mixed phosphonate derivatives bearing cholic acid and l-amino acid moieties for the treatment of HBV.
AID678814TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT3-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID682181TP_TRANSPORTER: inhibition of PHA uptake (PHA: 1000uM) by P-aminohippuric acid at a concentration of 10uM in mOat3-expressing oocytes2004Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 32, Issue:5
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1219946Drug transport in human OAT1 expressed in HEK Flp-In cells2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681169TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681150TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Pflugers Archiv : European journal of physiology, Nov, Volume: 443, Issue:2
Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3.
AID681808TP_TRANSPORTER: inhibition of DNP-NAC uptake (DNP-NAC: 1 uM, PAH: 1000 uM) in Xenopus laevis oocytes2001Molecular pharmacology, Nov, Volume: 60, Issue:5
Mercapturic acids (N-acetylcysteine S-conjugates) as endogenous substrates for the renal organic anion transporter-1.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,139)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901293 (60.45)18.7374
1990's477 (22.30)18.2507
2000's261 (12.20)29.6817
2010's96 (4.49)24.3611
2020's12 (0.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.64 (24.57)
Research Supply Index7.74 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index76.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials64 (2.87%)5.53%
Reviews48 (2.15%)6.00%
Case Studies13 (0.58%)4.05%
Observational0 (0.00%)0.25%
Other2,106 (94.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]